Clinical Trials Insight: 700026927
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2008
At a glance
- Drugs INGN 225 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Introgen Therapeutics
- 14 Feb 2008 Status changed from planning to recruiting.
- 13 Sep 2007 New trial record.